Dr. Marcelo Bigal

Neurologista mais

Ribeirão Preto 2 endereços

Número de registro: CRM: 81671-SP RQE Nº: 89294

8 opiniões
Informações de contato
Informações de contato

Experiência

Dr. Marcelo Bigal é considerado uma das maiores autoridades mundiais no estudo das cefaléias. Radicado nos EUA desde 2001, foi professor de neurologia do Albert Einstein College of Medicine, em New York. Possui 330 publicações científicas, incluindo nas revistas de maior renome internacional, como o New England Journal of Medicine, Journal of the American Medical Association e Neurology. Tem 5 livros, alguns traduzidos em múltiplos idiomas e escreveu 42 capítulos de livros especializados em cefaléia e outras doenças neurológicas. Foi premiado por várias sociedades médicas, incluindo o “Harold-Wolff John Graham Award” da Academia Americana de Neurologia, por esforços extraordinários na pesquisa da dor, e o “Wolff Award“ da Academia Americana de Cefaléia pela melhor contribuição científica no ano. Recebeu outras 9 distinções internacionais e nacionais. Foi diretor científico da Sociedade Americana de Cefaléia por 4 anos, e da Sociedade Internacional de Cefaléia. Foi diretor das diretrizes de tratamento para a enxaqueca, da Academia Americana de Neurologia.

As pesquisas do Dr Bigal são consideradas fundamentais para o entendimento dos fatores de risco para a cronificação (aumento da frequência) da enxaqueca. Profundamente comprometido com o alívio de doença tão debilitante, Dr. Bigal liderou o desenvolvimento farmacêutico de um anticorpo monoclonal contra uma proteína (CGRP) de importância nesse processo. Esse medicamento foi aprovado a nível mundial, incluindo Estados Unidos (2018) e Brasil (2019), em esforço que durou 9 anos de desenvolvimento.

Atualmente o Dr. Bigal é CEO e presidente de companhia de Biotecnologia (Ventus Therapeutics) com laboratórios em Boston e Montreal. A companhia foi reconhecida em 2020 como uma das 10 mais promissoras start-up do mundo.
Dr. Bigal completou sua formação médica, residência em neurologia, mestrado e doutorado pela Faculdade de Medicina de Ribeirão Preto – USP. Seu pós-doutorado foi feito no New England Center for Headaches, Stamford, CT,

Sua filosofia é de que apenas o profundo entendimento da doença, bem como do paciente acometido por ela, devem guiar o tratamento. A vulgarização do tratamento, a trivialização da dor, e a pressa em se conseguir resultados são incompatíveis com melhoras profundas e definitivas.
mais

Sobre mim

Dr. Marcelo Bigal é considerado uma das maiores autoridades mundiais no estudo das cefaléias. Radicado nos EUA desde 2001, foi professor de neurologia do Albert Einstein College of Medicine, em New York. Possui 330 publicações científicas, incluindo nas revistas de maior renome internacional, como o New England Journal of Medicine, Journal of the American Medical Association e Neurology. Tem 5 livros, alguns traduzidos em múltiplos idiomas e escreveu 42 capítulos de livros especializados em cefaléia e outras doenças neurológicas. Foi premiado por várias sociedades médicas, incluindo o “Harold-Wolff John Graham Award” da Academia Americana de Neurologia, por esforços extraordinários na pesquisa da dor, e o “Wolff Award“ da Academia Americana de Cefaléia pela melhor contribuição científica no ano. Recebeu outras 9 distinções internacionais e nacionais. Foi diretor científico da Sociedade Americana de Cefaléia por 4 anos, e da Sociedade Internacional de Cefaléia. Foi diretor das diretrizes de tratamento para a enxaqueca, da Academia Americana de Neurologia.

As pesquisas do Dr Bigal são consideradas fundamentais para o entendimento dos fatores de risco para a cronificação (aumento da frequência) da enxaqueca. Profundamente comprometido com o alívio de doença tão debilitante, Dr. Bigal liderou o desenvolvimento farmacêutico de um anticorpo monoclonal contra uma proteína (CGRP) de importância nesse processo. Esse medicamento foi aprovado a nível mundial, incluindo Estados Unidos (2018) e Brasil (2019), em esforço que durou 9 anos de desenvolvimento.

Atualmente o Dr. Bigal é CEO e presidente de companhia de Biotecnologia (Ventus Therapeutics) com laboratórios em Boston e Montreal. A companhia foi reconhecida em 2020 como uma das 10 mais promissoras start-up do mundo.
Dr. Bigal completou sua formação médica, residência em neurologia, mestrado e doutorado pela Faculdade de Medicina de Ribeirão Preto – USP. Seu pós-doutorado foi feito no New England Center for Headaches, Stamford, CT,

Sua filosofia é de que apenas o profundo entendimento da doença, bem como do paciente acometido por ela, devem guiar o tratamento. A vulgarização do tratamento, a trivialização da dor, e a pressa em se conseguir resultados são incompatíveis com melhoras profundas e definitivas.
Experiência em:
  • Dores de Cabeça

Experiência

Doctor
Marcelo Bigal

Neurologista

8 opiniões
Doenças tratadas
Mostrar mais detalhes
Experiências profissionais
  • Presidente e CEO - Ventus Therapeutics - Montreal e Boston - desde 2019
  • Chief Medical Officer - Labrys Biologics, San Mateo, California, EUA - 2013-2014
  • Professor de Neurologia - Albert Einstein College of Medicine - New York - NY - EUA - 2002-2008
  • Diretor Científico da Sociedade Americana de Cefaléia - EUA - 2006-2010
  • Diretor de Pesquisas - Montefiore Headache Center - New York - NY - EUA - 2003-2008
  • Diretor de Pesquisas - New England Center for Headaches - Stamford - CT - EUA - 2001-2005
  • Diretor dos Guidelines da Academia Americana de Neurologia para o Tratamento Agudo das Dores de Cabeça - 2009
  • Prática médica neurológica e em cefaléias - Ribeirão Preto - SP - Brasil - 1997-2001
Mostrar mais detalhes
Publicações
  • Lista de todas as publicações nesse link: https://pubmed.ncbi.nlm.nih.gov/?term=Bigal+M
  • Bigal ME, Walter S, Rapoport AM. Fremanezumab as a preventive treatment for episodic and chronic migraine. Expert Rev Neurother. 2019;19(8):719-728.
  • Bigal ME. Abuse-Deterrent OxyContin And Hepatitis C. Health Aff (Millwood). 2019;38(4):696.
  • Bigal ME, Rapoport AM, Silberstein SD, Walter S, Hargreaves RJ, Aycardi E. From LBR-101 to Fremanezumab for Migraine. CNS Drugs. 2018;32(11):1025-1037.
  • Bigal ME. Opioids vs Nonopioids for Chronic Back, Hip, or Knee Pain. JAMA. 2018;320(5):507.
  • Bigal ME, Dodick DW, Krymchantowski AV, VanderPluym JH, Tepper SJ, Aycardi E, Loupe PS, Ma Y, Goadsby PJ. TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points. Neurology. 2016;87(1):41-48.
  • Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015;79(6):886-895.
  • Bigal ME, Lipton RB, Newman LC, Pierce MW, Silberstein SD. Sumatriptan Iontophoretic Transdermal System Reduces Treatment-Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline - Results From a Randomized Controlled Trial. Headache. 2015;55(8):1124-1132.
  • Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14(11):1091-1100.
  • Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14(11):1081-1090.
  • Bigal ME, Walter S, Rapoport AM. The vasodilatory activity of CGRP: a response. Headache. 2014;54(4):748-749.
  • Bigal ME, Walter S, Bronson M, Alibhoy A, Escandon R. Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia. 2014;34(12):968-976.
  • Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs. 2014;28(5):389-399.
  • Bigal ME, Escandon R, Bronson M, Walter S, Sudworth M, Huggins JP, Garzone P. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia. 2014;34(7):483-492.
  • Bigal ME. BMS-927711 for the acute treatment of migraine. Cephalalgia. 2014;34(2):90-92.
  • Bigal ME. Clinical trials update - 2013: year in review. Headache. 2014;54(4):756.
  • Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache. 2013;53(8):1230-1244.
  • Bigal ME, Hargreaves RJ. Why does sleep stop migraine? Curr Pain Headache Rep. 2013;17(10):369.
  • Bigal ME. Clinical trials update--2012: year in review--a comment. Headache. 2013;53(6):1003-1004.
  • Bigal ME, Rapoport AM. Obesity and chronic daily headache. Curr Pain Headache Rep. 2012;16(1):101-109.
  • Bigal ME. Expert commentary -- unusual headache syndromes. Curr Pain Headache Rep. 2012;16(4):287-288.
  • Bigal ME. The association between migraine and obesity: empty calories? Cephalalgia. 2012;32(13):950-952.
  • Bigal ME, Lipton RB. Migraine chronification. Curr Neurol Neurosci Rep. 2011;11(2):139-148.
  • Bigal ME. Migraine and cardiovascular disease. Arq Neuropsiquiatr. 2011;69(1):122-129.
  • Bigal ME. Designing studies for cluster headache: lessons learned. Curr Pain Headache Rep. 2011;15(4):235-236.
  • Bigal ME. The paradoxical effects of analgesics and the development of chronic migraine. Arq Neuropsiquiatr. 2011;69(3):544-551.
  • Bigal ME. Tolerance to headache medications. Headache. 2011;51(8):1346-1349.
  • Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M, Lipton RB. Migraine and cardiovascular disease: a population-based study. Neurology. 2010;74(8):628-635.
  • Bigal ME, Golden W, Buse D, Chen YT, Lipton RB. Triptan use as a function of cardiovascular risk. A population-based study. Headache. 2010;50(2):256-263.
  • Bigal ME, Buse DC, Chen YT, Golden W, Serrano D, Chu MK, Lipton RB. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study. Headache. 2010;50(9):1440-1448.
  • Bigal ME, Arruda MA. Migraine in the pediatric population--evolving concepts. Headache. 2010;50(7):1130-1143.
  • Bigal ME. Migraine, lipid profile, and cardiovascular disease. Eur J Neurol. 2010;17(3):342-343.
  • Bigal ME. Phenothiazines in migraine treatment. Curr Pain Headache Rep. 2010;14(4):253-255.
  • Bigal ME. Migraine and cardiovascular disease. A call for action. Headache. 2010;50(5):882-883.
  • Bigal ME, Lipton RB, Biondi DM, Xiang J, Hulihan J. Weight change and clinical markers of cardiovascular disease risk during preventive treatment of migraine. Cephalalgia. 2009;29(11):1188-1196.
  • Bigal ME, Lipton RB. Excessive opioid use and the development of chronic migraine. Pain. 2009;142(3):179-182.
  • Bigal ME, Lipton RB. The epidemiology, burden, and comorbidities of migraine. Neurol Clin. 2009;27(2):321-334.
  • Bigal ME, Lipton RB. What predicts the change from episodic to chronic migraine? Curr Opin Neurol. 2009;22(3):269-276.
  • Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep. 2009;13(4):301-307.
  • Bigal ME, Kurth T, Hu H, Santanello N, Lipton RB. Migraine and cardiovascular disease: possible mechanisms of interaction. Neurology. 2009;72(21):1864-1871.
  • Bigal ME, Krymchantowski AV, Ho T. Migraine in the triptan era: progresses achieved, lessons learned and future developments. Arq Neuropsiquiatr. 2009;67(2B):559-569.
  • Bigal ME, Krymchantowski AV, Hargreaves R. The triptans. Expert Rev Neurother. 2009;9(5):649-659.
  • Bigal ME, Ho TW. Is there an inherent limit to acute migraine treatment efficacy? J Headache Pain. 2009;10(6):393-394.
  • Bigal ME, Ferrari M, Silberstein SD, Lipton RB, Goadsby PJ. Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science. Headache. 2009;49 Suppl 1:S21-33.
  • Bigal ME, Borucho S, Serrano D, Lipton RB. The acute treatment of episodic and chronic migraine in the USA. Cephalalgia. 2009;29(8):891-897.
  • Bigal ME. Re. Prevalence and associated factors for episodic and chronic daily headache in the Colombian population. Cephalalgia. 2009;29(7):799; author reply 799-800.
  • Bigal ME. Correlation of increase in phosphene threshold with reduction of migraine frequency: a comment. Headache. 2009;49(5):783-784.
  • Bigal ME. Diagnostic evaluation and treatment of trigeminal neuralgia. Curr Pain Headache Rep. 2009;13(4):256-257.
  • Bigal M, Krymchantowski AV, Lipton RB. Barriers to satisfactory migraine outcomes. What have we learned, where do we stand? Headache. 2009;49(7):1028-1041.
  • Bigal M. Migraine chronification--concept and risk factors. Discov Med. 2009;8(42):145-150.
  • Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71(8):559-566.
  • Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48(8):1157-1168.
  • Bigal ME, Rapoport AM, Hargreaves R. Advances in the pharmacologic treatment of tension-type headache. Curr Pain Headache Rep. 2008;12(6):442-446.
  • Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache. 2008;48(1):7-15.
  • Bigal ME, Lipton RB. Migraine in adolescents: towards an easy-to-use screening tool. Nat Clin Pract Neurol. 2008;4(5):246-247.
  • Bigal ME, Lipton RB. Obesity and chronic daily headache. Curr Pain Headache Rep. 2008;12(1):56-61.
  • Bigal ME, Lipton RB. The prognosis of migraine. Curr Opin Neurol. 2008;21(3):301-308.
  • Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology. 2008;71(11):848-855.
  • Bigal ME, Lipton RB. Putative mechanisms of the relationship between obesity and migraine progression. Curr Pain Headache Rep. 2008;12(3):207-212.
  • Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71(22):1821-1828.
  • Bigal ME, Hetherington H, Pan J, Tsang A, Grosberg B, Avdievich N, Friedman B, Lipton RB. Occipital levels of GABA are related to severe headaches in migraine. Neurology. 2008;70(22):2078-2080.
  • Bigal ME, Gladstone J. The metabolic headaches. Curr Pain Headache Rep. 2008;12(4):292-295.
  • Bigal ME, Ashina S, Burstein R, Reed ML, Buse D, Serrano D, Lipton RB, Group A. Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology. 2008;70(17):1525-1533.
  • Bigal ME. Insulin metabolism is altered in migraineurs. A new pathogenic mechanism for migraine? A comment. Headache. 2008;48(4):644-645.
  • Bigal M, Sheftell F, Tepper S, Tepper D, Ho TW, Rapoport A. A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. Headache. 2008;48(9):1286-1293.
  • Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache. 2008;48(9):1337-1342.
  • Bigal ME, Tsang A, Loder E, Serrano D, Reed ML, Lipton RB. Body mass index and episodic headaches: a population-based study. Arch Intern Med. 2007;167(18):1964-1970.
  • Bigal ME, Sheftell FD, Tepper SJ, Rapoport AM. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia. 2007;27(6):568; author reply 568-569.
  • Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. The International Classification of Headache Disorders revised criteria for chronic migraine-field testing in a headache specialty clinic. Cephalalgia. 2007;27(3):230-234.
  • Bigal ME, Lipton RB, Winner P, Reed ML, Diamond S, Stewart WF, group Aa. Migraine in adolescents: association with socioeconomic status and family history. Neurology. 2007;69(1):16-25.
  • Bigal ME, Lipton RB, Holland PR, Goadsby PJ. Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology. 2007;68(21):1851-1861.
  • Bigal ME, Lipton RB. The differential diagnosis of chronic daily headaches: an algorithm-based approach. J Headache Pain. 2007;8(5):263-272.
  • Bigal M, Rapoport A, Aurora S, Sheftell F, Tepper S, Dahlof C. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache. 2007;47(4):475-479.
  • Bigal ME, Tepper SJ, Sheftell FD, Rapoport AM, Lipton RB. Field testing alternative criteria for chronic migraine. Cephalalgia. 2006;26(4):477-482.
  • Bigal ME, Sheftell FD, Tepper SJ, Rapoport AM. Migraine and silent infarcts. Are we making the proper decisions? Cephalalgia. 2006;26(5):629-630.
  • Bigal ME, Lipton RB. When migraine progresses: transformed or chronic migraine. Expert Rev Neurother. 2006;6(3):297-306.
  • Bigal ME, Lipton RB. The preventive treatment of migraine. Neurologist. 2006;12(4):204-213.
  • Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology. 2006;67(2):252-257.
  • Bigal ME, Lipton RB. Modifiable risk factors for migraine progression (or for chronic daily headaches)--clinical lessons. Headache. 2006;46 Suppl 3:S144-146.
  • Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006;46(9):1334-1343.
  • Bigal ME, Lipton RB. Migraine at all ages. Curr Pain Headache Rep. 2006;10(3):207-213.
  • Bigal ME, Liberman JN, Lipton RB. Obesity and migraine: a population study. Neurology. 2006;66(4):545-550.
  • Bigal ME, Liberman JN, Lipton RB. Age-dependent prevalence and clinical features of migraine. Neurology. 2006;67(2):246-251.
  • Bigal ME, Krymchantowski AV. Migraine triggered by sucralose--a case report. Headache. 2006;46(3):515-517.
  • Bigal ME, Krymchantowski AV. Emerging drugs for migraine prophylaxis and treatment. MedGenMed. 2006;8(2):31.
  • Bigal ME, Kolodner KB, Lafata JE, Leotta C, Lipton RB. Patterns of medical diagnosis and treatment of migraine and probable migraine in a health plan. Cephalalgia. 2006;26(1):43-49
  • Bigal ME, Gironda M, Tepper SJ, Feleppa M, Rapoport AM, Sheftell FD, Lipton RB. Headache prevention outcome and body mass index. Cephalalgia. 2006;26(4):445-450.
  • Bigal ME, Sheftell FD, Tepper SJ, Rapoport AM, Lipton RB. Migraine days decline with duration of illness in adolescents with transformed migraine. Cephalalgia. 2005;25(7):482-487.
  • Bigal ME, Rapoport AM, Tepper SJ, Sheftell FD, Lipton RB. The classification of chronic daily headache in adolescents--a comparison between the second edition of the international classification of headache disorders and alternative diagnostic criteria. Headache. 2005;45(5):582-589.
  • Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Chronic migraine is an earlier stage of transformed migraine in adults. Neurology. 2005;65(10):1556-1561.
  • Bigal ME, Lipton RB. Tension-type headache: classification and diagnosis. Curr Pain Headache Rep. 2005;9(6):423-429.
  • Bigal ME, Tepper SJ, Sheftell FD, Rapoport AM, Lipton RB. Chronic daily headache: correlation between the 2004 and the 1988 International Headache Society diagnostic criteria. Headache. 2004;44(7):684-691.
  • Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes. Cephalalgia. 2004;24(6):483-490.
  • Bigal ME, Lipton RB, Tepper SJ, Rapoport AM, Sheftell FD. Primary chronic daily headache and its subtypes in adolescents and adults. Neurology. 2004;63(5):843-847.
  • Bigal ME, Lipton RB, Stewart WF. The epidemiology and impact of migraine. Curr Neurol Neurosci Rep. 2004;4(2):98-104.
  • Bigal ME, Lipton RB, Krymchantowski AV. The medical management of migraine. Am J Ther. 2004;11(2):130-140.
  • Bigal ME, Krymchantowski AV, Rapoport AM. Prophylactic migraine therapy: emerging treatment options. Curr Pain Headache Rep. 2004;8(3):178-184.
  • Bigal ME, Tepper SJ. Ergotamine and dihydroergotamine: a review. Curr Pain Headache Rep. 2003;7(1):55-62.
  • Bigal ME, Sheftell FD, Rapoport AM, Tepper SJ, Weeks R, Baskin SM. MMPI personality profiles in patients with primary chronic daily headache: a case-control study. Neurol Sci. 2003;24(3):103-110.
  • Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache. 2003;43(4):336-342.
  • Bigal ME, Rapoport AM, Camel M. Cluster headache as a manifestation of intracranial inflammatory myofibroblastic tumour: a case report with pathophysiological considerations. Cephalalgia. 2003;23(2):124-128.
  • Bigal ME, Rapoport AM, Bordini CA, Tepper SJ, Sheftell FD, Speciali JG. Burden of migraine in Brazil: estimate of cost of migraine to the public health system and an analytical study of the cost-effectiveness of a stratified model of care. Headache. 2003;43(7):742-754.
  • Bigal ME, Lipton RB, Silberstein SD. Re: chronic daily headache in children and adolescents presenting to tertiary headache clinics. Headache. 2003;43(4):419-421.
  • Bigal ME, Lipton RB, Cohen J, Silberstein SD. Epilepsy and migraine. Epilepsy Behav. 2003;4 Suppl 2:S13-24.
  • Bigal ME, Lipton RB. Acute Treatment of Migraine Headache. Curr Treat Options Neurol. 2003;5(6):423-430.
  • Bigal ME, Krymchantowski AV, Rapoport AM. New developments in migraine prophylaxis. Expert Opin Pharmacother. 2003;4(4):433-443.
  • Bigal ME, Bordini CA, Antoniazzi AL, Speciali JG. The triptan formulations: a critical evaluation. Arq Neuropsiquiatr. 2003;61(2A):313-320.
  • Bigal ME, Tepper SJ, Sheftell FD, Rapoport AM. Hemicrania continua: a report of ten new cases. Arq Neuropsiquiatr. 2002;60(3-B):695-698.
  • Bigal ME, Tepper SJ, Rapoport AM, Sheftell FD. Hemicrania continua: comparison between two different classification systems. Cephalalgia. 2002;22(3):242-245.
  • Bigal ME, Sheftell FD, Rapoport AM, Tepper SJ, Lipton RB. Chronic daily headache: identification of factors associated with induction and transformation. Headache. 2002;42(7):575-581.
  • Bigal ME, Sheftell FD, Rapoport AM, Lipton RB, Tepper SJ. Chronic daily headache in a tertiary care population: correlation between the International Headache Society diagnostic criteria and proposed revisions of criteria for chronic daily headache. Cephalalgia. 2002;22(6):432-438.
  • Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ. Long-term follow-up of patients treated for chronic daily headache with analgesic overuse. Cephalalgia. 2002;22(4):327-328; author reply 328.
  • Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ. New migraine preventive options: an update with pathophysiological considerations. Rev Hosp Clin Fac Med Sao Paulo. 2002;57(6):293-298.
  • Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia. 2002;22(5):345-353.
  • Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double blind, placebo controlled study. Headache. 2002;42(9):862-871.
  • Bigal ME, Bordini CA, Speciali JG. [Efficacy of three drugs in the treatment of migrainous aura: a randomized placebo-controlled study]. Arq Neuropsiquiatr. 2002;60(2-B):406-409.
  • Bigal ME, Bordini CA, Speciali JG. [Intramuscular diclofenac in the acute treatment of migraine: a double-blind placebo controlled study]. Arq Neuropsiquiatr. 2002;60(2-B):410-415.
  • Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the acute treatment of episodic tension-type headache: a randomized, placebo controlled, double-blind study. Arq Neuropsiquiatr. 2002;60(3-A):537-541.
  • Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med. 2002;23(2):141-148.
  • Bigal ME, Bordini CA, Speciali JG. Intravenous dipyrone for the acute treatment of episodic tension-type headache: a randomized, placebo-controlled, double-blind study. Braz J Med Biol Res. 2002;35(10):1139-1145.
  • Bigal ME, Bordini CA, Sheftell FD, Speciali JG, Bigal JO. Migraine with aura versus migraine without aura: pain intensity and associated symptom intensities after placebo. Headache. 2002;42(9):872-877.
  • Bigal ME. To use or not to use dipyrone? Sao Paulo Med J. 2002;120(2):63.
  • Bigal ME, Moraes FA, Fernandes LC, Bordini CA, Speciali JG. Indirect costs of migraine in a public Brazilian hospital. Headache. 2001;41(5):503-508.
  • Bigal ME, Bordini CA, Speciali JG. Intravenous metamizol (Dipyrone) in acute migraine treatment and in episodic tension-type headache--a placebo-controlled study. Cephalalgia. 2001;21(2):90-95.
  • Bigal ME, Bordini CA, Speciali JG. Daily headache as a manifestation of lithium intoxication. Neurology. 2001;57(9):1733-1734.
  • Bigal ME, Bigal JO, Bordini CA, Speciali JG. Prevalence and costs of headaches for the public health system in a town in the interior of the state of Sao Paulo. Arq Neuropsiquiatr. 2001;59(3-A):504-511.
  • Bigal ME, Bigal JO, Bordini CA, Speciali JG. [Evaluation of placebo use in migraine without aura, migraine with aura and episodic tension-type headache acute attacks]. Arq Neuropsiquiatr. 2001;59(3-A):552-558.
  • Bigal ME, Bigal JM, Betti M, Bordini CA, Speciali JG. Evaluation of the impact of migraine and episodic tension-type headache on the quality of life and performance of a university student population. Headache. 2001;41(7):710-719.
  • Bigal ME, Fernandes LC, Moraes FA, Bordini CA, Speciali JG. [Migraine prevalence and impact in employees of the clinical hospital of the medical school of Ribeirao Preto-USP]. Arq Neuropsiquiatr. 2000;58(2B):431-436.
  • Bigal ME, Fernandes LC, Bordini CA, Speciali JG. [Hospital costs of acute headaches in a Brazilian public emergency room unit]. Arq Neuropsiquiatr. 2000;58(3A):664-670.
  • Bigal ME, Bordini CA, Speciali JG. Etiology and distribution of headaches in two Brazilian primary care units. Headache. 2000;40(3):241-247.
  • Bigal M, Bordini CA, Speciali JG. Headache in an emergency room in Brazil. Sao Paulo Med J. 2000;118(3):58-62.
  • Bigal ME, Bordini CA, Speciali JG. [Headache treatment in an emergency unit of the city of Ribeirao Preto, Brazil]. Arq Neuropsiquiatr. 1999;57(3B):813-819.
  • Bigal ME, Hoffmann A, Menescal-de-Oliveira L. Alteration of the motor response to an acute painful stimulus during tonic immobility. Braz J Med Biol Res. 1994;27(4):1071-1075.
  • Arruda MA, Arruda R, Guidetti V, Bigal ME. ADHD Is Comorbid to Migraine in Childhood: A Population-Based Study. J Atten Disord. 2020;24(7):990-1001.
  • Silberstein SD, Rapoport AM, Loupe PS, Aycardi E, McDonald M, Yang R, Bigal ME. The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment. Headache. 2019;59(3):383-393.
  • VanderPluym J, Dodick DW, Lipton RB, Ma Y, Loupe PS, Bigal ME. Fremanezumab for preventive treatment of migraine: Functional status on headache-free days. Neurology. 2018;91(12): .
  • Arruda MA, Chevis CF, Bigal ME. Recent advances in the management of chronic migraine in children. Expert Rev Neurother. 2018;18(3):231-239.
  • Peres MFP, Mercante JPP, Tobo PR, Kamei H, Bigal ME. Anxiety and depression symptoms and migraine: a symptom-based approach research. J Headache Pain. 2017;18(1):37.
  • Feleppa M, Fucci S, Bigal ME. Primary Headaches in an Elderly Population Seeking Medical Care for Cognitive Decline. Headache. 2017;57(2):209-216.
  • Cohen JM, Dodick DW, Yang R, Newman LC, Li T, Aycardi E, Bigal ME. Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines. Headache. 2017;57(9):1375-1384.
  • Walter S, Bigal ME. TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine. Curr Pain Headache Rep. 2015;19(3):6.
  • Sparaco M, Feleppa M, Bigal ME. Cerebral Venous Thrombosis and Headache--A Case-Series. Headache. 2015;55(6):806-814.
  • Rapoport AM, Meskunas CA, Bigal ME. Commentary on Westergaard's "Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: A systematic review". Cephalalgia. 2015;35(7):637-638.
  • Arruda MA, Arruda R, Guidetti V, Bigal ME. Psychosocial adjustment of children with migraine and tension-type headache - a nationwide study. Headache. 2015;55 Suppl 1:39-50.
  • Walter S, Alibhoy A, Escandon R, Bigal ME. Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. MAbs. 2014;6(4):871-878.
  • Sanges G, Gamerra M, Sorrentino G, De Luca R, Merone M, Feleppa M, Bigal ME. Endoscopic sinus surgery in individuals with facial pain due to chronic maxillary sinusitis - a functional controlled study. Arq Neuropsiquiatr. 2014;72(8):609-612.
  • Goncalves DA, Camparis CM, Speciali JG, Castanharo SM, Ujikawa LT, Lipton RB, Bigal ME. Treatment of comorbid migraine and temporomandibular disorders: a factorial, double-blind, randomized, placebo-controlled study. J Orofac Pain. 2013;27(4):325-335.
  • Krymchantowski AV, da Cunha Jevoux C, Bigal ME. Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders. J Headache Pain. 2012;13(1):53-59.
  • Goncalves DA, Camparis CM, Franco AL, Fernandes G, Speciali JG, Bigal ME. How to investigate and treat: migraine in patients with temporomandibular disorders. Curr Pain Headache Rep. 2012;16(4):359-364.
  • Arruda MA, Bigal ME. Migraine and behavior in children: influence of maternal headache frequency. J Headache Pain. 2012;13(5):395-400.
  • Arruda MA, Bigal ME. Behavioral and emotional symptoms and primary headaches in children: a population-based study. Cephalalgia. 2012;32(15):1093-1100.
  • Arruda MA, Bigal ME. Migraine and migraine subtypes in preadolescent children: association with school performance. Neurology. 2012;79(18):1881-1888.
  • Sanges G, Feleppa M, Gamerra M, Sorrentino G, De Luca R, Merone M, Cacace L, Bigal ME. Fronto-turbinalis sinus expansion and headache. Curr Pain Headache Rep. 2011;15(4):308-313.
  • Ng-Mak DS, Fitzgerald KA, Norquist JM, Banderas BF, Nelsen LM, Evans CJ, Healy CG, Ho TW, Bigal M. Key concepts of migraine postdrome: a qualitative study to develop a post-migraine questionnaire. Headache. 2011;51(1):105-117.
  • Ho TW, Bigal M. Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine: a response. Headache. 2011;51(4):617-618.
  • Grossi DB, Chaves TC, Goncalves MC, Moreira VC, Canonica AC, Florencio LL, Bordini CA, Speciali JG, Bigal ME. Pressure pain threshold in the craniocervical muscles of women with episodic and chronic migraine: a controlled study. Arq Neuropsiquiatr. 2011;69(4):607-612.
  • Goncalves DA, Camparis CM, Speciali JG, Franco AL, Castanharo SM, Bigal ME. Temporomandibular disorders are differentially associated with headache diagnoses: a controlled study. Clin J Pain. 2011;27(7):611-615.
  • Arruda MA, Guidetti V, Galli F, Albuquerque RC, Bigal ME. Prenatal exposure to tobacco and alcohol are associated with chronic daily headaches at childhood: A population-based study. Arq Neuropsiquiatr. 2011;69(1):27-33.
  • Arruda MA, Bonamico L, Stella C, Bordini CA, Bigal ME. Cluster headache in children and adolescents: ten years of follow-up in three pediatric cases. Cephalalgia. 2011;31(13):1409-1414.
  • Arruda MA, Albuquerque RC, Bigal ME. Uncommon headache syndromes in the pediatric population. Curr Pain Headache Rep. 2011;15(4):280-288.
  • Speciali JG, Peres M, Bigal ME. Migraine treatment and placebo effect. Expert Rev Neurother. 2010;10(3):413-419.
  • Scher AI, Lipton RB, Stewart WF, Bigal M. Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study. Cephalalgia. 2010;30(3):321-328.
  • Scher A, Lipton R, Bigal M. Response to 'comments on results of Scher et al. pertaining to nonprescription caffeine-containing combination analgesics'. Cephalalgia. 2010;30(12):1535-1536.
  • Lipton RB, Bigal ME. The social impact and burden of headache. Handb Clin Neurol. 2010;97:23-32.
  • Katic BJ, Krause SJ, Tepper SJ, Hu HX, Bigal ME. Adherence to acute migraine medication: what does it mean, why does it matter? Headache. 2010;50(1):117-129.
  • Gladstone J, Bigal ME. Headaches attributable to infectious diseases. Curr Pain Headache Rep. 2010;14(4):299-308.
  • Bianchin MM, Londero RG, Lima JE, Bigal ME. Migraine and epilepsy: a focus on overlapping clinical, pathophysiological, molecular, and therapeutic aspects. Curr Pain Headache Rep. 2010;14(4):276-283.
  • Bevilaqua-Grossi D, Lipton RB, Napchan U, Grosberg B, Ashina S, Bigal ME. Temporomandibular disorders and cutaneous allodynia are associated in individuals with migraine. Cephalalgia. 2010;30(4):425-432.
  • Arruda MA, Guidetti V, Galli F, Albuquerque RC, Bigal ME. Frequent headaches in the preadolescent pediatric population: a population-based study. Neurology. 2010;74(11):903-908.
  • Arruda MA, Guidetti V, Galli F, Albuquerque RC, Bigal ME. Frequency of headaches in children is influenced by headache status in the mother. Headache. 2010;50(6):973-980.
  • Arruda MA, Guidetti V, Galli F, Albuquerque RC, Bigal ME. Primary headaches in childhood--a population-based study. Cephalalgia. 2010;30(9):1056-1064.
  • Arruda MA, Guidetti V, Galli F, Albuquerque RC, Bigal ME. Migraine, tension-type headache, and attention-deficit/hyperactivity disorder in childhood: a population-based study. Postgrad Med. 2010;122(5):18-26.
  • Arruda MA, Guidetti V, Galli F, Albuquerque RC, Bigal ME. Childhood periodic syndromes: a population-based study. Pediatr Neurol. 2010;43(6):420-424.
  • Sarmento E, Moreira P, Brito C, Souza J, Jevoux C, Bigal M. Proton spectroscopy in patients with post-traumatic headache attributed to mild head injury. Headache. 2009;49(9):1345-1352.
  • Ng-Mak DS, Hu XH, Bigal M. Migraine treatment with rizatriptan and almotriptan: a crossover study. Headache. 2009;49(5):655-662.
  • Kung E, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. New daily persistent headache in the paediatric population. Cephalalgia. 2009;29(1):17-22.
  • Hu H, Kurth T, Cady R, Santanello N, Bigal ME. Acute migraine treatment with rizatriptan in real world settings - focusing on treatment strategy, effectiveness, and behavior. Headache. 2009;49 Suppl 1:S34-42.
  • Ho TW, Rodgers A, Bigal ME. Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache. 2009;49(3):395-403.
  • Goncalves DA, Speciali JG, Jales LC, Camparis CM, Bigal ME. Temporomandibular symptoms, migraine, and chronic daily headaches in the population. Neurology. 2009;73(8):645-646.
  • Bevilaqua-Grossi D, Pegoretti KS, Goncalves MC, Speciali JG, Bordini CA, Bigal ME. Cervical mobility in women with migraine. Headache. 2009;49(5):726-731.
  • Bevilaqua Grossi D, Lipton RB, Bigal ME. Temporomandibular disorders and migraine chronification. Curr Pain Headache Rep. 2009;13(4):314-318.
  • Antoniazzi AL, Bigal ME. Expert opinion: Headaches and hemodialysis. Headache. 2009;49(3):463-466.
  • Tepper SJ, Zatochill M, Szeto M, Sheftell F, Tepper DE, Bigal M. Development of a simple menstrual migraine screening tool for obstetric and gynecology clinics: the menstrual migraine assessment tool. Headache. 2008;48(10):1419-1425.
  • Peterlin BL, Tietjen G, Meng S, Lidicker J, Bigal M. Post-traumatic stress disorder in episodic and chronic migraine. Headache. 2008;48(4):517-522.
  • Nicholson R, Bigal M. Screening and behavioral management: obesity and weight management. Headache. 2008;48(1):51-57.
  • Lipton RB, Bigal ME. Looking to the future: research designs for study of headache disease progression. Headache. 2008;48(1):58-66.
  • Lipton RB, Bigal ME. Headache as a real disease. Headache. 2008;48(5):707-710.
  • Lipton RB, Bigal ME. Toward an epidemiology of refractory migraine: current knowledge and issues for future research. Headache. 2008;48(6):791-798.
  • Krymchantowski AV, Bryson J, Lipton RB, Bigal ME. Neuromodulators for the treatment of headache disorders and fibromyalgia. Curr Pain Headache Rep. 2008;12(5):333-337.
  • Feleppa M, Apice G, D'Alessio A, Fucci S, Bigal ME. Tolerability of acute migraine medications: influence of methods of assessment and relationship with headache attributes. Cephalalgia. 2008;28(10):1012-1016.
  • Ashina S, Lipton RB, Bigal ME. Treatment of comorbidities of chronic daily headache. Curr Treat Options Neurol. 2008;10(1):36-43.
  • Tepper SJ, Sheftell FD, Bigal ME. The patent foramen ovale-migraine question. Neurol Sci. 2007;28 Suppl 2:S118-123.
  • Tepper DE, Tepper SJ, Sheftell FD, Bigal ME. Headache attributed to hypothyroidism. Curr Pain Headache Rep. 2007;11(4):304-309.
  • Sheftell FD, Tepper SJ, Lay CL, Bigal ME. Post-traumatic headache: emphasis on chronic types following mild closed head injury. Neurol Sci. 2007;28 Suppl 2:S203-207.
  • Rapoport AM, Mathew NT, Silberstein SD, Dodick D, Tepper SJ, Sheftell FD, Bigal ME. Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study. Neurology. 2007;69(9):821-826.
  • Lipton RB, Bigal ME. Migraine and cardiovascular disease: is there a link? Nat Clin Pract Neurol. 2007;3(2):74-75.
  • RB, Bigal ME. Ten lessons on the epidemiology of migraine. Headache. 2007;47 Suppl 1:S2-9.
  • Volcy M, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. Botulinum toxin A for the treatment of greater occipital neuralgia and trigeminal neuralgia: a case report with pathophysiological considerations. Cephalalgia. 2006;26(3):336-340.
  • Volcy M, Rapoport AM, Tepper SJ, Sheftell FD, Bigal ME. Persistent idiopathic facial pain responsive to topiramate. Cephalalgia. 2006;26(4):489-491.
  • Vogler B, Rapoport AM, Tepper SJ, Sheftell F, Bigal ME. Role of melatonin in the pathophysiology of migraine: implications for treatment. CNS Drugs. 2006;20(5):343-350.
  • Speciali JG, Bigal ME. Subcortical lesions in migraine: are they related to mitochondrial dysfunction? Headache. 2006;46(9):1461-1462.
  • Sparaco M, Feleppa M, Lipton RB, Rapoport AM, Bigal ME. Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia. 2006;26(4):361-372.
  • Rapoport AM, Tepper SJ, Sheftell FD, Kung E, Bigal ME. Which triptan for which patient? Neurol Sci. 2006;27 Suppl 2:S123-129.
  • Meskunas CA, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache. 2006;46(5):766-772.
  • Lipton RB, Bigal ME. Migraine and cardiovascular disease. JAMA. 2006;296(3):332-333.
  • Krymchantowski AV, Oliveira T, Bigal ME. Side-locked headache as the chief complaint of inflammatory orbital pseudotumor (myositic form): a case report. Headache. 2006;46(4):683-686.
  • Krymchantowski AV, Filho PF, Bigal ME. Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study. Cephalalgia. 2006;26(7):871-874.
  • Krymchantowski AV, Bigal ME. Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach. Expert Rev Neurother. 2006;6(3):283-289.
  • Behin F, Lipton RB, Bigal M. Migraine and intranasal contact point headache: is there any connection? Curr Pain Headache Rep. 2006;10(4):312-315.
  • Volcy M, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. Short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA)--a case report. Cephalalgia. 2005;25(6):470-472.
  • Volcy M, Sheftell FD, Tepper SJ, Rapoport AM, Bigal ME. Tinnitus in migraine: an allodynic symptom secondary to abnormal cortical functioning? Headache. 2005;45(8):1083-1087.
  • Sheftell FD, Tepper SJ, Bigal ME. Migraine: barriers for care. Neurol Sci. 2005;26 Suppl 2:s140-142.
  • Sheftell FD, Rapoport AM, Tepper SJ, Bigal ME. Naratriptan in the preventive treatment of refractory transformed migraine: a prospective pilot study. Headache. 2005;45(10):1400-1406.
  • Rapoport AM, Sheftell FD, Tepper SJ, Bigal ME. Levetiracetam in the preventive treatmentof transformed migraine: A prospective, open-label, pilot study. Curr Ther Res Clin Exp. 2005;66(3):212-221.
  • Rapoport AM, Bigal ME. Migraine preventive therapy: current and emerging treatment options. Neurol Sci. 2005;26 Suppl 2:s111-120.
  • Lipton RB, Bigal ME. Headache: triumphs in translational research. Lancet Neurol. 2005;4(1):11-12.
  • Lipton RB, Bigal ME. Epidemiology of migraine in Latin America: an editorial. Headache. 2005;45(2):103-104.
  • Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache. 2005;45 Suppl 1:S3-S13.
  • Lipton RB, Bigal ME. The epidemiology of migraine. Am J Med. 2005;118 Suppl 1:3S-10S.
  • Lipton RB, Bigal ME. Headache research methodology. Headache. 2005;45(5):535-537.
  • Krymchantowski AV, Bigal ME. Rofecoxib in migraine. Expert Rev Neurother. 2005;5(1):55-61.
  • Krymchantowski AV, Bigal ME. Rizatriptan in migraine. Expert Rev Neurother. 2005;5(5):597-603.
  • Sheftell FD, Feleppa M, Tepper SJ, Volcy M, Rapoport AM, Bigal ME. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache. 2004;44(7):661-668.
  • Sheftell FD, Feleppa M, Tepper SJ, Rapoport AM, Ciannella L, Bigal ME. Assessment of adverse events associated with triptans--methods of assessment influence the results. Headache. 2004;44(10):978-982.
  • Rapoport AM, Bigal ME. Preventive migraine therapy: what is new. Neurol Sci. 2004;25 Suppl 3:S177-185.
  • Rapoport AM, Bigal ME. ID-migraine. Neurol Sci. 2004;25 Suppl 3:S258-260.
  • Prince PB, Rapoport AM, Sheftell FD, Tepper SJ, Bigal ME. The effect of weather on headache. Headache. 2004;44(6):596-602.
  • Lipton RB, Bigal ME. Opioid therapy and headache: a cause and a cure. Neurology. 2004;62(10):1662-1663.
  • Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol. 2004;4:10.
  • Rapoport AM, Bigal ME. The clinical spectrum of migraine. Compr Ther. 2003;29(1):35-42.
  • Rapoport AM, Bigal ME. Hemicrania continua: clinical and nosographic update. Neurol Sci. 2003;24 Suppl 2:S118-121.
  • Lipton RB, Bigal ME. Chronic daily headache: is analgesic overuse a cause or a consequence? Neurology. 2003;61(2):154-155.
  • Pinheiro CF, Moraes R, Carvalho GF, Sestari L, Will-Lemos T, Bigal ME, Dach F, van Emmerik R, Bevilaqua-Grossi D. The Influence of Photophobia on Postural Control in Patients With Migraine. Headache. 2020;60(8):1644-1652.
  • Jassar H, Nascimento TD, Kaciroti N, DosSantos MF, Danciu T, Koeppe RA, Smith YR, Bigal ME, Porreca F, Casey KL, Zubieta JK, DaSilva AF. Impact of chronic migraine attacks and their severity on the endogenous mu-opioid neurotransmission in the limbic system. Neuroimage Clin. 2019;23:101905.
  • Halker Singh RB, Aycardi E, Bigal ME, Loupe PS, McDonald M, Dodick DW. Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials. Cephalalgia. 2019;39(1):52-60.
  • Fernandes G, Arruda MA, Bigal ME, Camparis CM, Goncalves DAG. Painful Temporomandibular Disorder Is Associated With Migraine in Adolescents: A Case-Control Study. J Pain. 2019;20(10):1155-1163.
  • Carvalho GF, Vianna-Bell FH, Florencio LL, Pinheiro CF, Dach F, Bigal ME, Bevilaqua-Grossi D. Presence of vestibular symptoms and related disability in migraine with and without aura and chronic migraine. Cephalalgia. 2019;39(1):29-37.
  • Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. 2018;319(19):1999-2008.
  • Carvalho GF, Florencio LL, Pinheiro CF, Dach F, Bigal ME, Bevilaqua-Grossi D. Functional Balance Deterioration on Daily Activities in Patients With Migraine: A Controlled Study. Am J Phys Med Rehabil. 2018;97(2):90-95.
  • Carvalho GF, Almeida CS, Florencio LL, Pinheiro CF, Dach F, Bigal ME, Bevilaqua-Grossi D. Do patients with migraine experience an increased prevalence of falls and fear of falling? A cross-sectional study. Physiotherapy. 2018;104(4):424-429.
  • Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017;377(22):2113-2122.
  • Kopruszinski CM, Xie JY, Eyde NM, Remeniuk B, Walter S, Stratton J, Bigal M, Chichorro JG, Dodick D, Porreca F. Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents. Cephalalgia. 2017;37(6):560-570.
  • Jordani PC, Campi LB, Circeli GZ, Visscher CM, Bigal ME, Goncalves DA. Obesity as a risk factor for temporomandibular disorders. J Oral Rehabil. 2017;44(1):1-8.
  • Florencio LL, de Oliveira AS, Carvalho GF, Dach F, Bigal ME, Fernandez-de-Las-Penas C, Bevilaqua-Grossi D. Association Between Severity of Temporomandibular Disorders and the Frequency of Headache Attacks in Women With Migraine: A Cross-Sectional Study. J Manipulative Physiol Ther. 2017;40(4):250-254.
  • Carvalho GF, Bonato P, Florencio LL, Pinheiro CF, Dach F, Bigal ME, Bevilaqua-Grossi D. Balance Impairments in Different Subgroups of Patients With Migraine. Headache. 2017;57(3):363-374.
  • Benatto MT, Florencio LL, Carvalho GF, Dach F, Bigal ME, Chaves TC, Bevilaqua-Grossi D. Cutaneous allodynia is more frequent in chronic migraine, and its presence and severity seems to be more associated with the duration of the disease. Arq Neuropsiquiatr. 2017;75(3):153-159.
  • Gutman D, Hellriegel E, Aycardi E, Bigal ME, Kunta J, Chitra R, Kansagra S, Kidron OS, Knebel H, Linder S, Ma Y, Pierce M, Winner PK, Spiegelstein O. A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients. Headache. 2016;56(8):1300-1309.
  • Florencio LL, Oliveira AS, Lemos TW, Carvalho GF, Dach F, Bigal ME, Falla D, Fernandez-de-Las-Penas C, Bevilaqua-Grossi D. Patients with chronic, but not episodic, migraine display altered activity of their neck extensor muscles. J Electromyogr Kinesiol. 2016;30:66-72.
  • Chaves TC, Dach F, Florencio LL, Carvalho GF, Goncalves MC, Bigal ME, Speciali JG, Bevilaqua-Grossi D. Concomitant Migraine and Temporomandibular Disorders are Associated With Higher Heat Pain Hyperalgesia and Cephalic Cutaneous Allodynia. Clin J Pain. 2016;32(10):882-888.
  • Carvalho GF, Chaves TC, Florencio LL, Dach F, Bigal ME, Bevilaqua-Grossi D. Reduced thermal threshold in patients with Temporomandibular Disorders. J Oral Rehabil. 2016;43(6):401-408.
  • Bevilaqua-Grossi D, Goncalves MC, Carvalho GF, Florencio LL, Dach F, Speciali JG, Bigal ME, Chaves TC. Additional Effects of a Physical Therapy Protocol on Headache Frequency, Pressure Pain Threshold, and Improvement Perception in Patients With Migraine and Associated Neck Pain: A Randomized Controlled Trial. Arch Phys Med Rehabil. 2016;97(6):866-874.
  • Florencio LL, de Oliveira AS, Carvalho GF, Tolentino Gde A, Dach F, Bigal ME, Fernandez-de-las-Penas C, Bevilaqua Grossi D. Cervical Muscle Strength and Muscle Coactivation During Isometric Contractions in Patients With Migraine: A Cross-Sectional Study. Headache. 2015;55(10):1312-1322.
  • Chagas OF, Eckeli FD, Bigal ME, Silva MO, Speciali JG. Study of the use of analgesics by patients with headache at a specialized outpatient clinic (ACEF). Arq Neuropsiquiatr. 2015;73(7):586-592.
  • Arruda MA, Querido CN, Bigal ME, Polanczyk GV. ADHD and mental health status in Brazilian school-age children. J Atten Disord. 2015;19(1):11-17.
  • Melhado EM, Bigal ME, Galego AR, Galdezzani JP, Queiroz LP. Headache classification and aspects of reproductive life in young women. Arq Neuropsiquiatr. 2014;72(1):17-23.
  • Florencio LL, Chaves TC, Carvalho GF, Goncalves MC, Casimiro EC, Dach F, Bigal ME, Bevilaqua-Grossi D. Neck pain disability is related to the frequency of migraine attacks: a cross-sectional study. Headache. 2014;54(7):1203-1210.
  • De Luca Canto G, Singh V, Bigal ME, Major PW, Flores-Mir C. Association between tension-type headache and migraine with sleep bruxism: a systematic review. Headache. 2014;54(9):1460-1469.
  • Zimmerman ME, Bigal ME, Katz MJ, Derby CA, Lipton RB. Are sleep onset/maintenance difficulties associated with medical or psychiatric comorbidities in nondemented community-dwelling older adults? J Clin Sleep Med. 2013;9(4):363-369.
  • Goncalves MC, Florencio LL, Chaves TC, Speciali JG, Bigal ME, Bevilaqua-Grossi D. Do women with migraine have higher prevalence of temporomandibular disorders? Braz J Phys Ther. 2013;17(1):64-68.
  • Fernandes G, Franco AL, Goncalves DA, Speciali JG, Bigal ME, Camparis CM. Temporomandibular disorders, sleep bruxism, and primary headaches are mutually associated. J Orofac Pain. 2013;27(1):14-20.
  • Carvalho GF, Chaves TC, Dach F, Pinheiro CF, Goncalves MC, Florencio LL, Ferreira KS, Bigal ME, Bevilaqua-Grossi D. Influence of migraine and of migraine aura on balance and mobility--a controlled study. Headache. 2013;53(7):1116-1122.
  • Zimmerman ME, Bigal ME, Katz MJ, Brickman AM, Lipton RB. Sleep onset/maintenance difficulties and cognitive function in nondemented older adults: the role of cognitive reserve. J Int Neuropsychol Soc. 2012;18(3):461-470.
  • Stuginski-Barbosa J, Dach F, Bigal M, Speciali JG. Chronic pain and depression in the quality of life of women with migraine--a controlled study. Headache. 2012;52(3):400-408.
  • Silva Junior AA, Bigal M, Vasconcelos LP, Rodrigues J, Gomez RS, Krymchantowski AV, Moreira Filho P, Teixeira AL. Prevalence and burden of headaches as assessed by the health family program. Headache. 2012;52(3):483-490.
  • Maleki N, Becerra L, Brawn J, Bigal M, Burstein R, Borsook D. Concurrent functional and structural cortical alterations in migraine. Cephalalgia. 2012;32(8):607-620.
  • Florencio LL, Chaves TC, Branisso LB, Goncalves MC, Dach F, Speciali JG, Bigal ME, Bevilaqua-Grossi D. 12 item allodynia symptom checklist/Brasil: cross-cultural adaptation, internal consistency and reproducibility. Arq Neuropsiquiatr. 2012;70(11):852-856.
  • Chu MK, Buse DC, Bigal ME, Serrano D, Lipton RB. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(2):213-223.
  • Maleki N, Becerra L, Nutile L, Pendse G, Brawn J, Bigal M, Burstein R, Borsook D. Migraine attacks the Basal Ganglia. Mol Pain. 2011;7:71.
  • Cohen JM, Bigal ME, Newman LC. Migraine and vestibular symptoms--identifying clinical features that predict "vestibular migraine". Headache. 2011;51(9):1393-1397.
  • Stuginski-Barbosa J, Macedo HR, Bigal ME, Speciali JG. Signs of temporomandibular disorders in migraine patients: a prospective, controlled study. Clin J Pain. 2010;26(5):418-421.
  • Goncalves DA, Dal Fabbro AL, Campos JA, Bigal ME, Speciali JG. Symptoms of temporomandibular disorders in the population: an epidemiological study. J Orofac Pain. 2010;24(3):270-278.
  • Goncalves DA, Bigal ME, Jales LC, Camparis CM, Speciali JG. Headache and symptoms of temporomandibular disorder: an epidemiological study. Headache. 2010;50(2):231-241.
  • Franco AL, Goncalves DA, Castanharo SM, Speciali JG, Bigal ME, Camparis CM. Migraine is the most prevalent primary headache in individuals with temporomandibular disorders. J Orofac Pain. 2010;24(3):287-292.
  • Bendtsen L, Bigal ME, Cerbo R, Diener HC, Holroyd K, Lampl C, Mitsikostas DD, Steiner TJ, Tfelt-Hansen P, International Headache Society Clinical Trials S. Guidelines for controlled trials of drugs in tension-type headache: second edition. Cephalalgia. 2010;30(1):1-16.
  • Sun-Edelstein C, Bigal ME, Rapoport AM. Chronic migraine and medication overuse headache: clarifying the current International Headache Society classification criteria. Cephalalgia. 2009;29(4):445-452.
  • Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, Bigal M, Ascher S, Morein J, Wright P, Greenberg S, Hulihan J. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009;49(8):1153-1162.
  • Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339:b3914.
  • McCarthy LH, Bigal ME, Katz M, Derby C, Lipton RB. Chronic pain and obesity in elderly people: results from the Einstein aging study. J Am Geriatr Soc. 2009;57(1):115-119.
  • Lipton RB, Kolodner K, Bigal ME, Valade D, Lainez MJ, Pascual J, Gendolla A, Bussone G, Islam N, Albert K, Parsons B. Validity and reliability of the Migraine-Treatment Optimization Questionnaire. Cephalalgia. 2009;29(7):751-759.
  • Hazard E, Munakata J, Bigal ME, Rupnow MF, Lipton RB. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value Health. 2009;12(1):55-64.
  • Diener HC, Dodick DW, Goadsby PJ, Bigal ME, Bussone G, Silberstein SD, Mathew N, Ascher S, Morein J, Hulihan JF, Biondi DM, Greenberg SJ. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia. 2009;29(10):1021-1027.
  • Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009;49(9):1258-1266.
  • Stuginski-Barbosa J, Rodrigues GG, Bigal ME, Speciali JG. Burning mouth syndrome responsive to pramipexol. J Headache Pain. 2008;9(1):43-45.
  • Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, Serrano D, Stewart WF, American Migraine Prevalence Prevention Advisory G. Cutaneous allodynia in the migraine population. Ann Neurol. 2008;63(2):148-158.
  • Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Saper J, Ascher S, Jordan DM, Greenberg SJ, Hulihan J, Topiramate Chronic Migraine Study G. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47(2):170-180.
  • Silberstein S, Loder E, Diamond S, Reed ML, Bigal ME, Lipton RB, Group AA. Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study. Cephalalgia. 2007;27(3):220-229.
  • Peterlin BL, Bigal ME, Tepper SJ, Urakaze M, Sheftell FD, Rapoport AM. Migraine and adiponectin: is there a connection? Cephalalgia. 2007;27(5):435-446.
  • Nieri A, Bazan R, Almeida L, Rocha FC, Raffin CN, Bigal ME, Schelp AO. Bilateral painful idiopathic ophthalmoplegia: a case report. Headache. 2007;47(6):848-851.
  • Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, Group AA. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-349.
  • Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 2007;47(3):355-363.
  • Stewart WF, Bigal ME, Kolodner K, Dowson A, Liberman JN, Lipton RB. Familial risk of migraine: variation by proband age at onset and headache severity. Neurology. 2006;66(3):344-348.
  • Martins KM, Bordini CA, Bigal ME, Speciali JG. Migraine in the elderly: a comparison with migraine in young adults. Headache. 2006;46(2):312-316.
  • Haut SR, Bigal ME, Lipton RB. Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol. 2006;5(2):148-157.
  • Evans RW, Bigal ME, Grosberg B, Lipton RB. Target doses and titration schedules for migraine preventive medications. Headache. 2006;46(1):160-164.
  • Scher AI, Bigal ME, Lipton RB. Comorbidity of migraine. Curr Opin Neurol. 2005;18(3):305-310.
  • Lipton RB, Bigal ME, Stewart WF. Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life. Neurology. 2005;65(12 Suppl 4):S50-58.
  • Grosberg BM, Lantos G, Lipton RB, Bigal ME, Solomon S. New onset headache in a woman with recurrent ear infections. Headache. 2005;45(3):240-241.
  • Castano A, Volcy M, Garcia FA, Uribe CS, Bigal ME, Restrepo M. Headache in symptomatic intracranial hypertension secondary to leptospirosis: a case report. Cephalalgia. 2005;25(4):309-311.
  • Behin F, Behin B, Bigal ME, Lipton RB. Surgical treatment of patients with refractory migraine headaches and intranasal contact points. Cephalalgia. 2005;25(6):439-443.
  • Tepper SJ, Bigal ME, Sheftell FD, Rapoport AM. Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases. Headache. 2004;44(8):794-800.
  • Sheftell FD, Bigal ME, Tepper SJ, Rapoport AM. Sumatriptan: a decade of use and experience in the treatment of migraine. Expert Rev Neurother. 2004;4(2):199-209.
  • Rapoport AM, Bigal ME, Tepper SJ, Sheftell FD. Intranasal medications for the treatment of migraine and cluster headache. CNS Drugs. 2004;18(10):671-685.
  • Rapoport AM, Bigal ME, Tepper SJ, Sheftell FD. Zolmitriptan (Zomig). Expert Rev Neurother. 2004;4(1):33-41.
  • Patel NV, Bigal ME, Kolodner KB, Leotta C, Lafata JE, Lipton RB. Prevalence and impact of migraine and probable migraine in a health plan. Neurology. 2004;63(8):1432-1438.
  • Lipton RB, Bigal ME, Steiner TJ, Silberstein SD, Olesen J. Classification of primary headaches. Neurology. 2004;63(3):427-435.
  • Lipton RB, Bigal ME, Rush SR, Yenkosky JP, Liberman JN, Bartleson JD, Silberstein SD. Migraine practice patterns among neurologists. Neurology. 2004;62(11):1926-1931.
  • Lipton RB, Bigal ME, Kolodner KB, Gorelick PB, Wilks K, Schoebelock M, Davidai G. Acetaminophen in the treatment of headaches associated with dipyridamole-aspirin combination. Neurology. 2004;63(6):1099-1101.
  • Lipton RB, Bigal ME, Goadsby PJ. Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review. Cephalalgia. 2004;24(5):321-332.
  • Lipton RB, Bigal ME, Amatniek JC, Stewart WF. Tools for diagnosing migraine and measuring its severity. Headache. 2004;44(5):387-398.
  • Grosberg BM, Lantos G, Solomon S, Bigal ME, Lipton RB. Multiple cranial neuropathies, headache, and facial pain in a septuagenarian. Headache. 2004;44(10):1038-1039.
  • Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD. The triptan formulations : how to match patients and products. CNS Drugs. 2003;17(6):431-447.
  • Rapoport AM, Bigal ME, Volcy M, Sheftell FD, Feleppa M, Tepper SJ. Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases. Headache. 2003;43(5):482-489.
  • Rapoport AM, Bigal ME, Tepper SJ, Sheftell FD. Treatment of cluster headache with topiramate: effects and side-effects in five patients. Cephalalgia. 2003;23(1):69-70; author reply 70.
  • Miziara L, Bigal ME, Bordini CA, Speciali JG. [Menstrual headache: semiological study in 100 cases]. Arq Neuropsiquiatr. 2003;61(3A):596-600.
  • Lipton RB, Silberstein SD, Saper JR, Bigal ME, Goadsby PJ. Why headache treatment fails. Neurology. 2003;60(7):1064-1070.
  • Lipton RB, Scher AI, Steiner TJ, Bigal ME, Kolodner K, Liberman JN, Stewart WF. Patterns of health care utilization for migraine in England and in the United States. Neurology. 2003;60(3):441-448.
  • Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia. 2003;23(6):441-450.
  • Lipton RB, Bigal ME, Stewart WF. Assessing disability using the migraine disability assessment questionnaire. Expert Rev Neurother. 2003;3(3):317-325.
  • Lipton RB, Bigal ME, Kolodner K, Stewart WF, Liberman JN, Steiner TJ. The family impact of migraine: population-based studies in the USA and UK. Cephalalgia. 2003;23(6):429-440.
  • Antoniazzi AL, Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Headache and hemodialysis: a prospective study. Headache. 2003;43(2):99-102.
  • Antoniazzi AL, Bigal ME, Bordini CA, Speciali JG. Headache associated with dialysis: the International Headache Society criteria revisited. Cephalalgia. 2003;23(2):146-149.
  • Krymchantowski AV, Bigal ME, Moreira PF. New and emerging prophylactic agents for migraine. CNS Drugs. 2002;16(9):611-634.
  • Antoniazzi AL, Bigal ME, Bordini CA, Speciali JG. [Headache and hemodialysis: evaluation of the possible triggering factors and of the treatment]. Arq Neuropsiquiatr. 2002;60(3-A):614-618.
Mostrar mais detalhes
Formação
  • Pós Doutorado pelo Albert Einstein College of Medicine (New York, EUA) - 2002
  • Doutorado em Neurologia (Cefaléias) pela Faculdade de Medicina de Ribeirão Preto - USP - 2001
  • Mestrado em Neurologia (Cefaléias) pela Faculdade de Medicina de Ribeirão Preto - USP - 2000
  • Residência em Neurologia pela Faculdade de Medicina de Ribeirão Preto - USP - 1997
  • Faculdade de Medicina de Ribeirão Preto - USP - 1994
Mostrar mais detalhes
Prêmios
  • Segundo pesquisador a receber o prestigioso prêmio Harold-Wolff John Graham Award, da Academia Americana de Neurologia, por extraordinários esforços na pesquisa das cefaléias e dor - The American Academy of Neurology 2005 Harold-Wolff John Graham Award for outstanding achievements in pain research;
  • Por dois anos consecutivos (2004 e 2005), prêmio Kapplan Award por pesquisa sobre cefaléias crônicas diárias, da Academia Americana de Cefaléia -• The American Headache Society 2004 and 2005 Kapplan awards for best research in chronic daily headache;.
  • Vencedor do Prestigioso Harold G. Wolff Award (2008), da Academia Americana de Cefaléias por melhor pesquisa científica em cefaléia. Disponivel abaixo.
  • https://headachejournal.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1526-4610.2008.01217.x
  • Vencedor do Preventive Research Award da American Headache Society por notáveis esforços na prevenção das cefaléias
  • Vencedor do 2007 International Congress Lecture Award pela melhor apresentação no Congresso da Sociedade Internacional de Cefaléia, em Estocolmo, Suécia
  • Vencedor do 2008 National Headache Foundation Lecture Award, pela melhor apresentação no congresso da Fundação Americana pelas Cefaléias
  • Companhia que preside figurou, em 2020, entre as 10 start-ups mais promissoras do mundo (https://www.businesswire.c1m/n1w1/h1m11n/V1ntu1-Th1rap1ut1c1-Nam1d-t1-C1-N1w1-10-1tart-Up1-t1-Watch-2020-L11t)
Mostrar mais detalhes
Agendar consulta

Consultórios (3)

Teleconsulta Endereço 1 Endereço 2
Este especialista não oferece agendamento online neste endereço

Teleconsulta

Teleconsulta (descrição) • R$ 780

Serviços

Consulta online

Os preços são para pacientes sem convênio médico
Teleconsulta
Teleconsulta • R$ 780

Primeira consulta para avaliação e conduta para o tratamento das dores de cabeça (enxaquecas, cefaléias em salvas, cefaléias pós-traumáticas e outras). Consiste em avaliação em detalhes da história atual e pregressa, discussão diagnóstica, e discussão do plano terapêutico a ser adotado. Tempo da primeira consulta é ao redor de uma hora.

Atende: adultos, crianças de qualquer idade
Este especialista pode prescrever receita médica eletrônica

Pelo menos 30 minutos antes da consulta, você receberá um SMS e e-mail com o link para a videochamada. Você poderá se conectar a partir do seu computador ou smartphone.

Prepare-se 10 minutos antes da consulta e verifique se o seu smartphone ou notebook está com a bateria carregada. Para uma videochamada, verifique se tudo funciona: conexão com a internet, câmera e microfone. Prepare também a documentação médica (como resultado de um exame) caso precise mostrar na consulta.

ampliar o mapa
Este especialista não oferece agendamento online neste endereço

Teleconsulta • R$ 780

Serviços

Dr. Marcelo E. Bigal

Teleconsulta • R$ 780

Este especialista não fornece todas as informações que você precisa?

Mostrar outros neurologistas perto de mim
Dr. Marcelo E. Bigal
Paraíso do Morumbi, Paraíso Do Morumbi , São Paulo
(mapa)
ampliar o mapa
Este especialista não oferece agendamento online neste endereço

Serviços

Dr. Marcelo E. Bigal

Consulta Neurologista

Este especialista não fornece todas as informações que você precisa?

Mostrar outros neurologistas perto de mim

Serviços e preços

Os preços são para pacientes sem convênio médico

Serviços em destaque

Teleconsulta

Outros serviços

Paraíso do Morumbi, São Paulo

Dr. Marcelo E. Bigal

As informações sobre preços são de responsabilidade do especialista ou centro. A Doctoralia não tem qualquer influência e não é responsável por definir os preços exibidos.

8 opiniões de pacientes

Enviar opinião

Classificação geral

Todas as opiniões são importantes, por isso os especialistas não podem pagar para alterar ou excluir uma opinião. Saiba mais.

Ordenar por

L
• Local: Consulta online • Teleconsulta

A experiência foi excelente. O Dr. Marcelo, além de muito qualificado, transmite tranquilidade e segurança ao paciente. Explica tudo de forma bastante detalhada e faz uma análise minuciosa do histórico médico de quem busca o seu auxílio. A empatia e a preocupação são singulares. Mostra-se disponível para eventuais dúvidas após a consulta, sempre retornando de forma breve. O melhor médico com quem já me consultei.

R
• Local: Consulta online • Teleconsulta

O Dr Marcelo é um profissional de competência extraordinária. Muito atencioso, sensato, experiente, com um olhar clínico e sabedoria sem igual. Extremante educado, aborda o problema de forma investigativa, clara e detalhada. Confio em seu trabalho. Só tenho a agradecer pela atenção e dedicação.

M
• Local: Consulta online • Teleconsulta

Dr. Marcelo foi muito atencioso, acolhedor e gentil antes, durante e após o atendimento. Demonstrou interesse no caso e disposição para conduzir o melhor tratamento, cuidando de todos os detalhes da minha história e olhando de forma integral às condições de saúde. Senti muita confiança na condução do caso. Sou muito grata!

A
• Local: Consulta online • Teleconsulta

Talvez eu não tenha tido uma consulta com um profissional tão atencioso, que busca a causa, não só os sintomas. Estou muito feliz e grata pela minha consulta, indico com certeza. Que sempre haja transbordos em sua vida e família dr Marcelo. Muito obrigada.

L
• Local: Consulta online • Teleconsulta

Exímio profissional, conhecimento extraordinário, atendimento humanizado, atencioso, esclarecedor e resolutivo.

R
Local: Consulta online • Teleconsulta

Ótima consulta. A experiência e cuidado do médico transparecem claramente durante a consulta. Sofro de cefaleia diária e já passei por muitos médicos e me sinto muito mais reassegurado sobre um futuro melhor.

M
Local: Consulta online • Teleconsulta

Extremamente atencioso, consulta detalhista e sem pressa. Valeu cada segundo da consulta. Obrigada Dr Marcelo.

A
Local: Consulta online • Teleconsulta

Consulta excepcional, super detalhista, atencioso e apesar de ser online, me senti presente como se estivesse no consultório!!!

Ocorreu um erro, tente outra vez

Dúvidas respondidas

12 dúvidas de pacientes respondidas na Doctoralia

Pergunta sobre Topamax

Comecei a tomar topiramato por causa da enxaqueca tem 16 dias. Parei de tomar a 4 dias , posso tomar cerveja ?

Sim, pode tomar cerveja, mas não deu tempo do topiramato atuar na sua enxaqueca. Ele demora pelo menos 6 semanas para fazer efeito real na enxaqueca.

Dr. Marcelo Bigal
Pergunta sobre Enxak

Posso tomar enxak? Amamento minha filha de 2 anos.

A ergotamina, um dos princípios ativos do enxak, interage com a prolactina, necessária para a produção do leite materno. Existem outros medicamentos para o tratamento agudo da enxaqueca que não interagem com a prolactina, portanto recomendo discutir com o (a) médico (a).

Dr. Marcelo Bigal
Ver todas as respostas

Todos os conteúdos publicados no doctoralia.com.br, principalmente perguntas e respostas na área da medicina, têm caráter meramente informativo e não devem ser, em nenhuma circunstância, considerados como substitutos de aconselhamento médico.

Pesquisas relacionadas
Neurologistas próximos

Neurologistas em Vila Virginia

Neurologistas em Alto Da Boa Vista

Neurologistas em Jardim Sumare

Neurologistas em Centro

Neurologistas em Jardim Nova Alianca

Neurologistas em Jardim Sao Luiz

Neurologistas em Jardim California

Mais (2)
Doenças mais tratadas

Cefaleia (dor de cabeça) em Ribeirão Preto

Doença de Alzheimer em Ribeirão Preto

Demência em Ribeirão Preto

Doença de Parkinson em Ribeirão Preto

Acidente vascular cerebral (AVC) em Ribeirão Preto

Tremor em Ribeirão Preto

Epilepsia em Ribeirão Preto

Enxaqueca em Ribeirão Preto

Convulsões em Ribeirão Preto

Tontura em Ribeirão Preto

Transtorno de déficit de atenção com hiperatividade (TDAH) em Ribeirão Preto

Esclerose Múltipla em Ribeirão Preto

Distonia em Ribeirão Preto

Doença do sono em Ribeirão Preto

Lombalgia (dor lombar) em Ribeirão Preto

Neuropatia Diabética em Ribeirão Preto

Ataxia em Ribeirão Preto

Doenças neurodegenerativas em Ribeirão Preto

Transtornos Da Memória em Ribeirão Preto

Insônia em Ribeirão Preto

Mais (15)
Convênios médicos mais populares

Neurologistas com Unimed em Ribeirão Preto

Neurologistas com Cassi em Ribeirão Preto

Neurologistas com Outro (Reembolso) em Ribeirão Preto

É necessário efetuar o pagamento da consulta

Seu especialista pede que você efetue o pagamento da consulta. Para reagendar, você pode pagar antecipadamente ou entrar em contato diretamente com seu especialista.
As minhas visitas Efetuar pagamento